Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sufentanil-dexmedetomidine versus remifentanil-acetaminophen for post-knee replacement pain control
IRCT20251123068087N1Phase 3Completed
- Sponsor
- Arak University of Medical Sciences
- Start
- Dec 2025
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, double-blind trial of sufentanil, dexmedetomidine, remifentanil and acetaminophen in postoperative pain and knee osteoarthritis (OA) (2 arms), sponsored by Arak University of Medical Sciences. Primary endpoint: Pain intensity. Started Dec 2025; status: completed.
02
Drugs
sufentanildexmedetomidineremifentanilacetaminophen
03
Conditions
postoperative painknee osteoarthritis (OA)
Beyond the preview
Go deeper on IRCT20251123068087N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20251123068087N1.